Saturday 17 October 2026
Export FBLG’s income statement to Excel — free account
FibroBiologics Inc.
FBLG Healthcare Biotechnology
In the quarter to June 2026, EPS grew 72.5% and free cash flow grew 21.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.95
0.05
−5.00%
Follow FBLG
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(1,292.87%) | (419.44%) | (754.75%) | (660.08%) | |
| (192.59%) | (143.08%) | (215.16%) | (166.14%) | ||
ROIC |
0.00% | (824.53%) | (960.76%) | (932.71%) | |
Return on Tangible Assets |
3,223.17% | (343.26%) | (1,008.64%) | (417.28%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(7.74) | (7.46) | (4.10) | (2.36) | |
Free Cash Flow |
(16.66) | (16.66) | (15.48) | (14.79) | |
Capital Expenditures |
(0.36) | (0.26) | — | — | |
| Other line items | |||||
Cash ROIC |
(174.23%) | (150.73%) | (379.30%) | (181.45%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
— | — | (859.30) | (760.41) | |
Operating CF/Net income |
0.88 | 0.88 | 0.83 | 0.82 | |
Depreciation/Fixed assets |
0.83 | 0.99 | 1.17 | 1.22 | |
Capex/Depreciation |
(0.48) | (0.31) | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(7.57) | (7.34) | (4.10) | (2.36) | |
Capex per Share |
(0.17) | (0.12) | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | — |
Columns are period end dates